CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine (Zynlonta®; ADC Therapeutics) targets CD19 and received accelerated approval from the FDA in 2021 and from the EMA in 2022 for relapsed/refractory B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL from low-grade lymphoma, and high-grade B-cell lymphoma.